MONTREAL--(BUSINESS WIRE)--Angiochem, Inc., a clinical-stage biotechnology company developing drugs uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that clinical data on its lead oncology program, ANG1005, will be highlighted at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL. ANG1005 is currently being studied for the treatment of brain cancers, including advanced solid tumors with brain metastases and glioblastoma (GBM).
